Abstract
Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine, and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase mortality and morbidity, as a weakened immune system can lead to a longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and their associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organization), U.S FDA (Food and Drug Administration), and other accredited global health organizations. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications, and drug-drug interactions. Our study will help government partners and international health organizations to understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised, and organ transplant patients will help lower the mortality and morbidity associated with the disease amid the COVID-19 pandemic.
Keywords: COVID-19, immunosuppressant drugs, etanercept, mycophenolate mofetil, sirolimus, cyclosporine, rituximab.
Coronaviruses
Title:Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Volume: 2 Issue: 12
Author(s): Debjyoti Talukdar, Diane Ignacio and Madan Mohan Gupta*
Affiliation:
- School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago,West Indies
Keywords: COVID-19, immunosuppressant drugs, etanercept, mycophenolate mofetil, sirolimus, cyclosporine, rituximab.
Abstract: Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine, and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase mortality and morbidity, as a weakened immune system can lead to a longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and their associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organization), U.S FDA (Food and Drug Administration), and other accredited global health organizations. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications, and drug-drug interactions. Our study will help government partners and international health organizations to understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised, and organ transplant patients will help lower the mortality and morbidity associated with the disease amid the COVID-19 pandemic.
Export Options
About this article
Cite this article as:
Talukdar Debjyoti, Ignacio Diane and Gupta Mohan Madan*, Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications, Coronaviruses 2021; 2 (12) : e070921193747 . https://dx.doi.org/10.2174/2666796702666210601125131
DOI https://dx.doi.org/10.2174/2666796702666210601125131 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinase Inhibitors Involved in the Regulation of Autophagy: Molecular
Concepts and Clinical Implications
Current Medicinal Chemistry Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Heart Failure in East Asia
Current Cardiology Reviews Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Editorial (Heart Failure: The Need for Global Health Perspective)
Current Cardiology Reviews Cardioprotective Role of <i>Tinospora cordifolia</i> against Trimethylamine-N-Oxide and Glucose Induced Stress in Rat Cardiomyocytes
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of ROS/inflammasome Axis is Essential for Cardiac Regeneration in Aging Rats Receiving Transplantation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Molecular Imaging of Myocardial Inflammation: More Evidence Toward a Causative Role in Cardiovascular Disease
Current Radiopharmaceuticals Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design